# A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung

> **NCT01154140** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 343 (actual)

## Conditions studied

- Non Squamous Lung Cancer

## Interventions

- **DRUG:** treatment
- **DRUG:** treatment

## Key facts

- **NCT ID:** NCT01154140
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-13
- **Primary completion:** 2013-11-30
- **Final completion:** 2016-11-30
- **Target enrollment:** 343 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01154140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01154140, "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01154140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*